POSTER HALL 3: Bioengineering 2024
Callan Monette
Osteosarcoma is a rare pediatric bone cancer characterized by high genomic complexity and high rates of chemoresistance, leading to longstanding challenges in its treatment.
VIEW POSTER SESSION
Tyler Singer-Clark
Brain-computer interfaces (BCIs) offer the potential to restore communication capabilities for people with paralysis due to neurological disease or injury such as ALS or stroke.
VIEW POSTER SESSION
Lucia Brunel
Corneal blindness affects more than 12.5 million people worldwide, yet less than 2% of patients have access to the human donor tissue needed for its conventional treatment.
VIEW POSTER SESSION
Robin Peter
Due to the short alpha-particle range and often heterogeneous distribution of targeting agents, cancer treatment using alpha-emitting radiopharmaceuticals can be subject to dose heterogeneity within target and non-target tissues.
VIEW POSTER SESSION
Quimby Lee
As a neuroengineer, my goal is to promote positive outcomes from neurodevelopmental diagnoses by developing accessible neuroimaging tools to better understand and characterize human brain development and its heterogeneous disorders.
VIEW POSTER SESSION
Devin Schoen
My research investigates leveraging T1-weighted magnetic resonance images as a consistent pre-operative source to uncover biomarkers associated with Deep Brain Stimulation (DBS) outcomes in Parkinson's disease patients.
VIEW POSTER SESSION
Carissa Garrity
Advanced tissue-engineering (TE) methods allow manufacturing of mechanically robust, biomimetic neo-cartilage from allogeneic cartilage cells (chondrocytes) due to their ease of availability and potential of manufacturing off-the-shelf implants.
VIEW POSTER SESSION